News
By Kashish Tandon (Reuters) -Indian drugmaker Anthem Biosciences' [ANTH.NS] $395 million IPO was fully subscribed on the ...
The Rs 3,395 crore Initial Public Offering (IPO) of Anthem Biosciences, the Bangalore-based contract research, development, ...
Indian drugmaker Anthem Biosciences' ANTH.NS $395 million public listing was fully subscribed on the second day of bidding, as investors bet on the company's growth prospects at a time when global big ...
Among investor categories, Non-Institutional Investors (NIIs) have shown the highest interest, bidding 1.55 times their ...
Anthem ticks all the boxes. But with lofty valuations and limited margin headroom, analysts warn the IPO may not deliver ...
Anthem Biosciences, ₹3,395 crore IPO was fully subscribed by Day 2, with strong interest from non-institutional investors, ...
Explore more
Anthem Biosciences' initial share sale received bids for 14,47,66,596 shares, as against 4,40,70,682 shares on offer, ...
With a unique business model rooted in innovation-led drug development services, the company is betting big on global ...
The mainline issue will close for public subscription on Wednesday, July 16. The basis of allotment of shares is likely to be ...
The grey market premium for Anthem Biosciences IPO rose from Rs 116 on Monday to Rs 123, as of 10:32 a.m., according to ...
Anthem Biosciences IPO on Day 2 with moderate success, price band ₹540-570, 35% reserved for retail investors.
18hon MSN
Anthem Biosciences raised ₹1,016.02 crore from 60 institutional investors ahead of its IPO launch on July 14. The offering, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results